Table 2 Allo-HCT in CTCL.
Ref | Subtype No. of patients | Prospective/retrospective/ phase | Treatment/conditioning | NRM | PFS | OS |
|---|---|---|---|---|---|---|
Duarte et al. 2010 | 36 MF 24 SS | Retrospective | 44 RIC 25 TCD | 1 yr; 20% 2 yr; 22% | 1 yr; 42% 3 yr; 34% | 1 yr; 66% 3 yr; 54% |
Duvic et al. 2010 | 19 | Prospective | RIC | NA | NA | Median not reached at 19 mo |
Delioukina et al. 2012 | 11 | Prospective | RIC | 2 yr; 22% | 2 yr; 47% | 2 yr; 55% |
Lechowicz et al. 2014 | SS 129 | Retrospective | 83 RIC 46 MAC | 1 yr; 19% 5 yr; 22% | 1 yr; 31% 5 yr; 17% | 1 yr; 54% 5 yr; 32% |
De Masson et al. 2014 | 37 | Retrospective | 25 RIC 12 MAC | 2 yr; 18% | 2 yr; 31% | 2 yr; 57% |
Hosing et al. 2015 | MF 30 SS 17 | Prospective | RIC | 3 yr; 17% | 4 yr; 26% | 4 yr; 51% |
Weng et al. 2020 | MF 13 SS 22 | Prospective phase II | TSEB/TLI/ATG | 2 yr; 14% | 3 yr; 41% | 3 yr; 26% |
Ritchie et al. 2020 | SS:4 MF:11 ALCL:2 | Retrospective | TSEB/TLI/ATG | 2 yr; 7% | – | 1 yr; 87% 2 yr; 79% |
Domingo-Domenech et al. 2021 | 113 | Prospective | 76% RIC | 5 yr; 28% | 5 yr; 26% | 5 yr; 38% |
Stamouli et al. 2021 | MF 8 SS 2 | Retrospective | Low-dose TBI fludarabine-Cy | 12% (mFU 20 mo) | 51 mo | 51 mo |
Elliott et al. 2021 | MF 17 SS 9 | Retrospective | 2 MAC 24 RIC | 17% | – | – |
De Masson et al. 2023 | 55 | Prospective | RIC | 10% | Median 9 mo | Median not reached at 12 mo |
Onida et al. 2024 (abstr) | MF 40 SS 23 | Retrospective | Low-dose TBI, fludarabine, melphalan | 5 yr 14% | 5 yr DFS 33% | 5 yr 53% |
